The Lancet published a series of correction notices on June 18, 2026, for four research articles spanning orthopedics, neurology, hematology, and global health. The corrections range from updating collaborator lists and author surnames to fixing data presentation errors.
One correction concerns the SCIENCE study on surgical fixation versus non-surgical care for children with displaced medial epicondyle fractures, while another involves the FASTEST trial on recombinant factor VIIa for intracerebral haemorrhage. A third addresses the ENERGIZE trial on mitapivat for thalassaemia, and the fourth corrects an affiliation in a Global Burden of Disease viewpoint.
Details vary by notice: the SCIENCE study updated its appendix collaborator list; the FASTEST trial corrected a surname for Ilana Spokoyny and replaced mentions of OR with least squared means in a table. The ENERGIZE study revised its list of investigators, and the GBD viewpoint fixed Morteza Shamsizadeh's affiliation to Hamadan University of Medical Sciences.
These corrections, all made to online versions as of June 18, 2026, highlight the ongoing process of ensuring accuracy in published medical research. No further details on the broader impact of these changes were provided in the notices.
The notices are routine for a major journal, reflecting standard post-publication review. However, the accumulation of errors across multiple high-profile trials raises questions about editorial oversight. Readers relying on these studies for clinical guidance should consult the updated versions.